Robert Bosch Gesellschaft für medizinische Forschung mbH
Robert Bosch Gesellschaft für medizinische Forschung mbH
Stuttgart, Germany6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression | interstitial lung disease, lung disorder, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT07540988 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-09-30 | NCT06238622 | |
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT07707895 | |
| Getinge's Beating Heart Product Family Post-Market Clinical Follow-up (PMCF) Study | Off Pump Coronary Artery Bypass Surgery | Recruiting | Not stated | 2026-09-11 | NCT07286890 | |
| Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder, injury, radiation injury | Recruiting | Not applicable | 2026-04-14 | NCT07528586 |